International Surgery Journal
Amaral MJ et al. Int Surg J. 2020 Jul;7(7):2378-2383
http://www.ijsurgery.com
pISSN 2349-3305 | eISSN 2349-2902
DOI: http://dx.doi.org/10.18203/2349-2902.isj20202852
Case Report
You are not yourself when you are hungry:
a rare case of malignant insulinoma
Maria Joao Amaral1,2*, Henrique Alexandrino1,2,3, Daniela Meireles4,
Rui Caetano Oliveira5, Marco Serodio1,2, Jose Guilherme Tralhao1,2,3
1
Department of General Surgery, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Faculty of Medicine, University of Coimbra, Coimbra, Portugal
3
Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment, Genetics and Oncobiology
(CIMAGO), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
4
Department of Internal Medicine, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal
5
Department of Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
2
Received: 03 April 2020
Revised: 08 June 2020
Accepted: 09 June 2020
*Correspondence:
Dr. Maria Joao Amaral,
E-mail: mariajoaoamaral@hotmail.com
Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial
use, distribution, and reproduction in any medium, provided the original work is properly cited.
ABSTRACT
We present a rare case of high-grade functional neuroendocrine carcinoma of the pancreas secreting insulin. Our
patient, an 80 years old woman, presented with neuropsychiatric symptoms consistent with hypoglycaemia that
regressed with food intake and dextrose administration. Abdominal imaging showed a pancreatic tumour with
invasion of the spleen and lymph node metastasis, highly suggestive of an insulinoma as the cause of the
hypoglycaemia. The patient underwent left pancreatectomy with splenectomy and atypical gastric resection. The
postoperative course of our patient was uneventful, with complete remission of the hypoglycaemic episodes, and the
definitive histological examination showed three poorly differentiated large cell neuroendocrine carcinomas of the
pancreas.
Keywords: Hypoglycaemia, Neurobehavioral manifestations, Neuroendocrine carcinoma, Insulinoma
INTRODUCTION
Pancreatic neuroendocrine tumours (NETs) compromise
less than 2% of all malignancies and are mostly nonfunctional 50-70%. Of those that are functional, they are
predominantly insulinomas and gastrinomas.1
Insulinoma is a pancreatic NET with an incidence of 4
cases per 1 million person-years and less than 10% of the
cases are malignant.2-4 Four features of insulinoma are
associated with four 90% parameters: 90% are benign,
90% are solitary, 90% occur in the pancreas and 90% are
less than 2 cm in diameter.4 Diagnosis is based on
symptoms of hypoglycaemia (endogenous hyperins-
ulinism), which are the main clinical manifestation and
are responsible for the morbidity of this tumour.2,4,5
Benign and malignant tumours are difficult to distinguish
clinically and, to the affected patients, the control of
glycaemia before surgery can be very problematic.3,6
Malignancy is defined by the presence of metastases that,
most commonly, are in the liver or lymph nodes.2,3
Surgery is the only curative treatment of malignant
insulinomas.2
We present a rare case of a neuroendocrine carcinoma
(NEC) with phenotypical behaviour of malignant
insulinoma causing neuropsychiatric symptoms that
relieved with food ingestion.
International Surgery Journal | July 2020 | Vol 7 | Issue 7
Page 2378
Amaral MJ et al. Int Surg J. 2020 Jul;7(7):2378-2383
CASE REPORT
An 80 years old woman was admitted to the emergency
department (ED) with a two-month history of morning
episodes of aggressive behaviour, periods of temporospatial disorientation, asthenia, polyphagia and nocturnal
diaphoresis. These symptoms occurred mostly in the
fasting state and alleviated by the ingestion of food. She
denied abdominal pain, nausea, vomiting, diarrhoea or
flushing.
receptors; splenic and gastric involvement were also
suspected, as well as of regional lymph nodes. Given the
constant need for intravenous dextrose perfusion and the
inability of the patient to endure a significant fasting
period, a decision was made to forego the performance of
a F-fluorodeoxyglucose-PET-CT scan.18
A
A
The patient had a history of atrial fibrillation, toxic
multinodular goitre, arterial hypertension, dyslipidemia
and degenerative osteoarticular disease, being medicated
with rivaroxaban, carvedilol, thiamazole, bromazepam,
atorvastatin and acemetacin. She denied any relevant
family history.
Neurological examination was normal. At the ED, the
head computed tomography (CT) was normal and she had
a blood glucose level of 38 mg/dl. Hypertonic glucose
30% was administered to normalize glucose
concentration and a perfusion of glucose at 5% was
maintained afterwards. The patient was admitted for
further investigation.
B
Investigations
Blood analysis showed a glucose level of 79 mg/dl with
perfusion of glucose at 5% and, after stopping the glucose
perfusion, the insulin level was 26.9mUI/l (r.v. 3-25) and
C-peptide was 6.08 ng/ml (r.v. 0.9-7.1); FSH (folliclestimulating hormone) and LH (luteinizing hormone) were
within normal values for her age, and the values of
oestradiol,
cortisol,
prolactin
and
ACTH
(adrenocorticotropic hormone) were also normal. She had
normal hepatic function tests and normal amylase and
lipase values. Blood tests were repeated and the insulin
level was 44mUI/l, C-peptide was 8.8ng/mL normal
glucose level with perfusion of glucose at 5% and
chromogranin A was 225 ng/ml (r.v. 19.4-98.1).
Figure 1: Computed tomography images of the
patient (A) arterial phase, displaying a large hypovascular mass with hyper-vascular areas in the body
and tail of the pancreas and (B) portal phase,
demonstrating direct extension to the splenic
parenchyma, as well as splenic vein obstruction.
Abdominal CT scan (Figure 1), revealed an enlarged
body and tail of the pancreas with an 80mm oval
formation with heterogeneous enhancement after
intravenous contrast administration, involving the splenic
artery in several of its segments, although it remained
patent; the mass extended to the splenic hilum with
involvement of the respective hilar vessels and to the
splenic parenchyma, where a vascularized 56mm
hypodense formation was present, suggesting direct
extension of the neoplasm to the splenic parenchyma.
Two enlarged lymph nodes, one at the emergence of the
celiac artery and the other one immediately below the
pancreatic tail, were also apparent.
Further diagnostic investigations included a Ga-DOTANOC positron-emission tomography CT (PET-CT),
which was highly suggestive of a NET of the pancreas
(Figure 2), with high expression of somatostatin
Figure 2: 68Ga-DOTA-NOC positron-emission
tomography CT (PET-CT) images tumour with a high
expression of somatostatin receptors can be seen in
the body and tail of the pancreas.
International Surgery Journal | July 2020 | Vol 7 | Issue 7
Page 2379
Amaral MJ et al. Int Surg J. 2020 Jul;7(7):2378-2383
In this case, the imaging procedures were indicative of an
insulinoma as the cause of the hypoglycaemic episodes.
Insulinoma frequently presents with neuroglycopenia,
which may cause cofusion and abnormal behaviours,
reversible with feeding, rather than the autonomic
symptoms, typically associated with more common
causes of hypoglycaemia.6
On gross examination of the specimen there were three
nodular lesions of the pancreas, one in the anterior part
with 2.2 cm and other in the posterior pancreas with 2
cm; the larger lesion was located in the pancreatic
body/tail and measured 6.5 cm. The latter tumour was
composed by a pinkish tissue, of soft consistency and
necrotic areas, and extended to the spleen and gastric
fundus (Figure 3).
Treatment and outcome
After multidisciplinary meeting, the diagnosis of
malignant pancreatic NET, with likely insulinoma-like
secretory phenotype, was made based on clinical and
imagological findings, and a decision for curative-intent
surgery was proposed. Through a left transverse
laparotomy with upper midline extension, abdominal
exploration revealed a large mass in the body and tail of
the pancreas, with direct extension to the splenic hilum
and
A invasion of the gastric fundus, without signs of
disseminated disease. Thus, a left pancreatectomy,
splenectomy and a bloc atypical resection of the gastric
fundus was performed.
A
B
C
D
Figure 5: (A and B) expansive growth of the two
smaller lesions, H and E (20X magnification),
(C) necrotic aeas in the large tumor, H and E (40X
magnification), (D) infiltrative behaviour of the large
tumour with invasion of the pancreatic adjacente
tissue, and (E) H and E (20X magnification).
A
Figure 3: Serial sections reveal a pink and soft tissue
mass, with invasion of the spleen.
A
B
B
Figure 6: (A) Chromogranin A, granular and diffuse
staining (200X magnification),
(B) synaptophysin, and diffuse staining (200x
magnification).
Figure 4: (A) Insular and trabecular neoplasm (40X
magnification) and (B) the tumoral cells had
eosinophilic cytoplasm, open coarse chromatin with
mitosis (400X magnification).
Histologic examination showed three large cell NEC,
with lympho-vascular and perineural invasion (pTNM-T3
(3) N0) (Figure 4). The smaller tumours had expansive
International Surgery Journal | July 2020 | Vol 7 | Issue 7
Page 2380
Amaral MJ et al. Int Surg J. 2020 Jul;7(7):2378-2383
growth (Figure 5), but the greater lesion exhibited
partially a pseudo-capsule of fibrotic tissue, with
disruption and invasion of splenic tissue and gastric
fundus. The neoplastic cells expressed, strongly and
diffusely, cam 5.2, synaptophysin and chromogranin A
(Figure 6). The ki67 proliferative index of the greater
lesion was 62% (Figure 7) and the mitotic rate was 25 per
10 high power field (HPF) (Figure 8). The smaller lesions
had a Ki67 proliferative index superior to 40% (Figure 9).
P53 was also overexpressed in all the three lesions.
Figure 7: MIB1 (ki67) proliferative index 62% of the
larger lesion (200X magnification).
Figure 8: The larger nodule exhibited high mitotic
activity, inclusively with atypical forms (arrow), H
and E (400X magnification).
A
B
Figure 9: Ki67 proliferative index of the smaller
lesions (200X magnification-A and 400x
magnification-B).
The post-operative course was uneventful and there was
complete remission of the hypoglycaemic episodes. Four
weeks after surgery the patient experienced no symptoms
in the fasting state, and her blood tests were within
normal values. On a subsequent multidisciplinary
meeting no adjuvant therapy was decided, only continued
surveillance.
DISCUSSION
Clinical hypoglycaemia occurs when the plasma glucose
concentration is low enough to cause symptoms and/or
signs, which include neurological symptoms, and
insulinoma should be suspected in patients who manifest
Whipple’s triad.6,7 Our patient presented with periods of
altered state of consciousness and aggressive behaviour
that ceased after normalizing her blood glucose levels.
This atypical presentation of hypoglycaemia is frequently
mistaken for a neuropsychiatric disorder and often results
in the missed or delayed diagnosis of the tumour, which
leads to a delayed treatment and to the risk of progressive
tumour growth, metastasis and death from severe
hypoglycaemia.6
As stated before, an insulinoma is the most common
cause of hypoglycaemia related to endogenous
hyperinsulinism, and it usually is a benign and sporadic
tumour. Although rare, it is the most common functioning
NET of the pancreas and should always be considered in
the differential diagnosis.7,8
The 72 hours fasting test remains the gold standard for
the diagnosis of insulinoma and includes the
measurement of plasma glucose, insulin and C-peptide, at
the time hypoglycaemic symptoms appear.8 Among noninvasive localization methods, CT yielded a sensitivity of
65-70%. As for somatostatin receptor imaging, it was
reported to generate a positive rate of 30 to 50%, with an
85.7% sensitivity for malignant insulinoma.4 This is
because insulinoma is usually benign and thus of small
size, unlike the case we report.
Liver metastasis upon disease onset is the most common
manifestation of malignant insulinoma. Rarely,
malignancy is diagnosed at the time of recurrence, which
occurs for only 2% of the insulinomas overall. The most
common metastatic sites of malignant insulinoma are the
abdomen, including the retroperitoneal lymph nodes and
liver, while bone, lung or other sites are rare.4
Camara-de-Sousa et al suggested a particular approach to
the patients with the following characteristics that suggest
a malignant insulinoma; clinical history of less than 6
months; fasting time before hypoglycaemia less than 8
hours; insulin and C-peptide concentration ≥2 μU/ml and
≥4 ng/dl at the glucose nadir, respectively, and a tumour
≥2.5 cm. CK19 status, the tumour staging and grading
(ki67>2%) and the age of onset >50 years can also be
considered indicators of malignancy.7 A very high level
of chromogranin A and proinsulin may indicate greater
potential for aggressive clinical behaviour, as well as a
histological grade 3 or more invasive grade 2. Although
these patients had shorter clinical presentations, the
International Surgery Journal | July 2020 | Vol 7 | Issue 7
Page 2381
Amaral MJ et al. Int Surg J. 2020 Jul;7(7):2378-2383
diagnosis was late, when most of them already displayed
disseminated disease.5 Our patient had a clinical history
of only 2 months and the tumour had already invaded the
spleen and stomach. We speculate whether the insulin
production was an acquired phenotype by some cell
clones of a pre-existing NET that was already growing to
a considerable size. This can be suggested by the
existence of hyper-vascular areas in the hypodense mass
on preoperative CT, as well as the three distinct tumours
on the final pathology. Surgery is the first-choice therapy
for re-sectable insulinomas and the only curative
option.2,8 Even unresectable cases can benefit from a
debulking surgery in the hope of controlling symptoms.9
Medical therapy can be useful both during the
preoperative period and for preventing hypoglycaemia in
insulinomas with unknown localization.8
Table 1: World health organization 2017 classification of the neuroendocrine neoplasm
of the pancreas (adapted from).1,14
Type
NEN
Mi NEN
Differentiation status
Well differentiated
Definition
NET
Poorly differentiated
NEC
Small cell type
Large cell type
Grade
G1
G2
G3
Mitotic rate
<2 per 10 HPF
2-20 per 10 HPF
>20 per 10 HPF
Ki-67 staining (%)
<3
3-20
>20
G3
>20 per 10 HPF
>20
Well/poorly differentiated
Abbreviations: NEN - neuroendocrine neoplasm; NET - neuroendocrine tumour; NEC - neuroendocrine carcinoma; Mi NEN - mixed
non-neuroendocrine - endocrine neoplasm; HPF - high power field.
Possible options are diazoxide, somatostatin analogs and
glucocorticoids.2,3,8 With our patient, we successfully
prevented hypoglycaemic episodes with the use of
continuous intravenous glucose infusion. Aggressive
secondary therapies such as chemoembolization or
radiofrequency ablation, in case of liver metastasis,
should only be used to control hypoglycaemia.3
Our patient’s case is rare. What seemed like an
insulinoma, turned out to be a high-grade NEC of the
pancreas at histological and immunohistochemical
examination (Table 1). Traditionally, grade 3 NEC are
considered non-functional.1 To our knowledge this is the
second reported case of functional insulin producing
high-grade NEC, presenting with symptoms of
hypoglycaemia.10 In our literature search, we have also
found a high-grade functional NEC of the pancreas
secreting vasoactive intestinal peptide.1
The existence of three nodules is also very interesting.
They could represent independent lesions or be a part of
the same lesions with foci of intrapancreatic
dissemination.11 Similar morphology, high Ki67
proliferative index as well as the P53 overexpression in
all the tumours provide some support to the latter theory
and genetic study could provide more information
regarding common mutations of clonal evolution.
However, it was not performed due to the lack of next
generation sequencing techniques in our institution.
Intrapancreatic metastasis is described for pancreatic
ductal adenocarcinoma so it is reason to believe that the
same phenomenon can happen with pancreatic NEC.12
The five years survival rate for malignant insulinomas
was described to be 55.6% and the ten years survival rate
has been reported to be 29%.4,6 For NEC, the overall 5
years survival of the patients is 17%.13 Thus, long-term
follow-up is mandatory.
Recurrence of the tumour after surgery, either in the form
of liver metastases or insulinomatosis, is usually
accompanied by hypoglycaemia, therefore these patients
should continue doing daily glucose levels
measurements.4
CONCLUSION
Malignant insulinoma is rare and the main clinical
manifestations are hypoglycaemia-related symptoms. De
novo neuropsychiatric symptoms, particularly arising in
the fasting state and alleviated by the ingestion of food,
should prompt the suspicion of insulinoma, although they
can be easily misdiagnosed as a primary neurocognitive
process.
Also, this case shows that NEC of the pancreas can rarely
have the potential to produce functional peptide
hormones and intrapancreatic metastasis probably can
occur. Surgery helps controlling symptoms of
hypoglycaemia,
completely
reversing
the
neuropsychiatric syndrome.
Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required
REFERENCES
1.
2.
Graham C, Chauhan A, Anthony L. Can a Highgrade Neuroendocrine Carcinoma be Functional.
Am J Med Sci. 2019;357(3):258-62.
Garcia FJC, Cruz GVI, Solis NDS, Andres CM,
Arino MC, Alfaro MA, et al. Management of
International Surgery Journal | July 2020 | Vol 7 | Issue 7
Page 2382
Amaral MJ et al. Int Surg J. 2020 Jul;7(7):2378-2383
3.
4.
5.
6.
7.
8.
9.
malignant insulinoma. Clin Transl Oncol.
2013;15:725-31.
Hirshberg B, Cochran C, Skarulis MC, Libutti SK,
Alexander HR, Wood BJ, et al. Malignant
Insulinoma: spectrum of unusual clinical features.
Cancer. 2005;104(2):264-72.
Yu J, Ping F, Zhang H, Li W, Yuan T, Fu Y, et al.
Clinical Management of Malignant Insulinoma: a
single Institution’s experience over three decades.
BMC Endocr Disord. 2018;18(1):92.
Camara-de-Souza AB, Toyoshima MTK, Giannela
ML, Freire DS, Camacho CP, Lourenço JDM, et al.
A retrospective study analysing the differences
between
benign
and
malignant
tumours.
Pancreatology. 2018;18(3):298-303.
Varela D, Yu A, Saxon D. Insulinoma
Masquerading
as
Transient
Neurocognitive
Impairment. Am J Med. 2018;131(9):377-9.
Caliri M, Verdiani V, Mannucci E, Briganti V,
Landoni L, Esposito A, et al. A case of malignant
insulinoma responsive to somatostatin analogs
treatment. BMC Endocr Disord. 2018;18(1):98.
Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A,
Ito S, Ogawa Y, et al. Diagnosis and management of
Insulinoma. World J Gastroenterol. 2013;19(6):82937.
Mathur A, Gorden P, Libutti SK. Insulinoma. Surg
Clin North Am. 2009;89(5):1105-21.
10. Sandoval MA, Pagsisihan D, Berberabe A, Lopez
PEG. A malignant cause of hypoglycaemia: a
metastatic
insulin-secreting
pancreatic
neuroendocrine carcinoma. BMJ Case Rep.
2016;2016:2016214702.
11. Crippa S, Partelli S, Belfiori G, Paluccci M,
Muffatti F, Adamenko O, et al. Management of
neuroendocrine carcinomas of the pancreas (WHO
G3): A tailored approach between proliferation and
morphology.
World
J
Gastroenterol.
2016;22(45):9944-53.
12. Fujita Y, Kitago M, Masugi Y, Tano O, Shinoda M,
Abe Y, et al. Two cases of pancreatic ductal
adenocarcinoma with intrapancreatic metastasis.
World J Gastroenterol. 2016;22(41):9222-8.
13. Fukushima N. Neuroendocrine Neoplasms of the
Pancreas: The Pathological View Point. J Pancreas.
2018;3:328-34.
14. Inzani F, Petrone G, Rindi G. The New World
Health Organization Classification for Pancreatic
Neuroendocrine Neoplasia. Endocrinol Metab Clin
N Am. 2018;47(3):463-70.
Cite this article as: Amaral MJ, Alexandrino H,
Meireles D, Oliveira RC, Serodio M, Tralhao JG.
You are not yourself when you are hungry: a rare
case of malignant insulinoma. Int Surg J
2020;7:2378-83.
International Surgery Journal | July 2020 | Vol 7 | Issue 7
Page 2383